BIBW 2992, a novel irreversible EGFR/HER2 tyrosine kinase inhibitor, in chemonaive patients with adenocarcinoma of the lung and activating EGFR mutations

被引：0

作者：

Yang Chih-Hsin ^{[1
]}

Shih Jin-Yuan ^{[1
]}

Su Wu-Chou ^{[2
]}

Hsia Te-Chun ^{[3
]}

Ho Ching-Liang ^{[4
]}

Dudek, Arkadiusz Z. ^{[5
]}

Terlizzi, Elizabeth ^{[6
]}

Zhao Yihua M ^{[6
]}

Shahidi, Mehdi ^{[7
]}

Miller, Vincent A. ^{[8
]}

机构：

[1] Natl Taiwan Univ Hosp, Taipei, Taiwan

[2] Natl Cheng Kung Univ Hosp, Tainan 70428, Taiwan

[3] China Med Univ Hosp, Taichung, Taiwan

[4] Tri Serv Gen Hosp, Taipei, Taiwan

[5] Univ Minnesota, Mason Canc Care Ctr, Minneapolis, MN USA

[6] Boehringer Ingelheim GmbH & Co KG, Ridgefield, CT USA

[7] Boehringer Ingelheim GmbH & Co KG, Bracknell, Berks, England

[8] Mem Sloan Kettering Canc Ctr, New York, NY 10021 USA

来源：

关键词：

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

引用

页码：S294 / S295

页数：2